Eculizumab in the treatment of neuromyelitis optica spectrum disorder

Sivertseva S.A.; Boyko O.V.; Boyko A.N.

doi:https://doi.org/10.17116/jnevro202512507260

Close metadata

Recommended articles:

Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118

Abstract:

The article describes a clinical case of a 48-year-old female patient with AQP4-positive with attacks neuromyelitis optica spectrum disorder (NMOSD). The article presents an assessment of the dynamics of the neurological status, as well as the results of laboratory and instrumental examination. A literature review is provided on the epidemiological features and modern approaches to the treatment of NMOSD. In a patient with a NMOSD with attacks course resistant to standard immunosuppressive therapy (glucocorticosteroids, azathioprine), the administration of eculizumab led to stable clinical remission. No exacerbations were recorded over 18 months of observation. Eculizumab demonstrates high efficiency in preventing NMOSD attacks and reducing the degree of disability in patients with AQP4-IgG-positive NMOSD with attacks and early administration of targeted therapy is critically important for preventing cumulative neurological damage, improving the prognosis and quality of life of patients with NMOSD.

Keywords:

NMOSD

aquaporin-4

eculizumab

complement

demyelination

Authors:

Sivertseva S.A.

AO MSCH «Neftyanik», Tyumen Regional Center for Multiple Sclerosis;
Ural State Medical University;
Kirov State Medical University

ORCID: 0000-0002-9293-5932

Boyko O.V.

Federal Center of Brain and Neurotechnologies

SPIN RSCI: 7244-5490
Scopus AuthorID: 55699162200
ORCID: 0000-0001-7153-5617

Boyko A.N.

Federal Center of Brain and Neurotechnologies;
N.I. Pirogov Russian National Research University (Pirogov University)

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Received:

24.06.2025

Accepted:

10.07.2025

Close metadata

References:

Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88:137-145. https://doi.org/10.1136/jnnp-2016-313300
Huda S, Whittam D, Bhojak M, et al. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-176. https://doi.org/10.7861/clinmedicine.19-2-169
Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers; 2020;6(1):85-91. https://doi.org/10.1038/s41572-020-0214-9
Zekeridou A, Lennon,VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e110. https://doi.org/10.1212/NXI.0000000000000110
Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2016;1366(1):20-39. https://doi.org/10.1111/nyas.12794
Takeshita Y, Obermeier B, Cotleur A, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311. https://doi.org/10.1212/NXI.0000000000000311
Yao X, Verkman AS. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun. 2017;5(1):15-21. https://doi.org/10.1186/s40478-017-0417-9
Yick LW, Ma OK, Ng RC, et al. Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice. Front Immunol. 2018;9:1438. https://doi.org/10.3389/fimmu.2018.01438
Cobo-Calvo A, Ruiz A, Richard C, et al. Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability. PLoS One. 2020;15(9):e0238301. https://doi.org/10.1371/journal.pone.0238301
Shimizu F, Schaller KL, Owens GP, et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med. 2017;9(397):eaai9111. https://doi.org/10.1126/scitranslmed.aai9111
Prasad S, Chen J. What You Need to Know About AQP4, MOG, and NMOSD. Semin Neurol. 2019;39(6):718-731. https://doi.org/10.1055/s-0039-3399505
Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. https://doi.org/10.1212/NXI.0000000000000572
Sepulveda M, Armangue T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e225. https://doi.org/10.1212/NXI.0000000000000225
Bennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e104. https://doi.org/10.1212/NXI.0000000000000104
Cotzomi E, Stathopoulos P, Lee CS, et al. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain. 2019;142(6):1598-1615. https://doi.org/10.1093/brain/awz106
Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. 2019;50(5):1132-1148. https://doi.org/10.1016/j.immuni.2019.04.011
Nicolas P, Ruiz A, Cobo-Calvo A, et al. The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. Front Immunol. 2019;10:2686. https://doi.org/10.3389/fimmu.2019.02686
Chen T, Bosco DB, Ying Y, et al. The Emerging Role of Microglia in Neuromyelitis Optica. Front Immunol. 2021;12:616301. https://doi.org/10.3389/fimmu.2021.616301
Guerrero BL, Sicotte NL. Microglia in Multiple Sclerosis: Friend or Foe? Front Immunol. 2020;11:374. https://doi.org/10.3389/fimmu.2020.00374
Krasnov VS, Bakhtiyarova KZ, Evdoshenko EP, et al. Consensus opinion on the management of patients with neuromyelitis optica spectrum disorders: issues of terminology and therapy. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):139-148. (In Russ.). https://doi.org/10.14412/2074-2711-2022-6-139-148
Wingerchuk DM, Fujihara K, Palace J, et al.; PREVENT Study Group. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol. 2021;89(6):1088-1098. https://doi.org/10.1002/ana.26049
Chan K, Lee CY. Treatment of Neuromyelitis Optica Spectrum Disorders. Int J Mol Sci. 2021;22(16):8638. https://doi.org/10.3390/ijms22168638
Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346-351. https://doi.org/10.1136/jnnp-2017-316286
Song W, Qu Y, Huang, X. Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. Int Ophthalmol. 2019;39(11):2477-2483. https://doi.org/10.1007/s10792-019-01090-z
Jacob S, Mazibrada G, Irani S., et al. The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. J Neuroimmune Pharmacol. 2021;16(4):806-817. https://doi.org/10.1007/s11481-021-10004-9
Kleiter I, Gahlen A, Borisow N, et al.; NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e504. https://doi.org/10.1212/NXI.0000000000000504
Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020;38:101506. https://doi.org/10.1016/j.msard.2019.101506
Yu HH, Qin C, Zhang SQ, et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. J Neuroimmunol. 2020;350:577449. https://doi.org/10.1016/j.jneuroim.2020.577449
Oji S, Nomura, K. Immunoadsorption in neurological disorders. Transfus Apher Sci. 2017;56(5):671-676. https://doi.org/10.1016/j.transci.2017.08.013
Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology — mode of action and clinical efficacy. Nat Rev Neurol. 2015, 11(2):80-89. https://doi.org/10.1038/nrneurol.2014.253
Li X, Tian DC, Fan M, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020;44:102325. https://doi.org/10.1016/j.msard.2020.102325
Mealy MA, Kim SH, Schmidt F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018, 24(13):1737-1742. https://doi.org/10.1177/1352458517730131
Instructions for medical use of the drug Ultomiris LP-No. (001862)-(RG-RU). (In Russ.). dated 03/28/2023 https://grls.rosminzdrav.ru/
Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614-625. https://doi.org/10.1056/NEJMoa1900866
Pittock SJ, Fujihara K, Palace J, et al.; PREVENT Study Group. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler. 2022, 28(3):480-486. https://doi.org/10.1177/13524585211038291
Briko NI. Resolution of the Interdisciplinary Expert Council on the prevention of severe infections in patients with genetic disorders of complement regulation receiving eculizumab therapy. Epidemiology and Vaccine Prevention. 2017;16(1):51-54. (In Russ.).
Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114-2124. https://doi.org/10.1056/NEJMoa1901747
Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412. https://doi.org/10.1016/S1474-4422(20)30078-8
Ringelstein M, Ayzenberg I, Harmel J, et al. Long-Term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015, 72(7):756-763. https://doi.org/10.1001/jamaneurol.2015.0533
Zhang C, Zhang M, Qiu W, et al.; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401. https://doi.org/10.1016/S1474-4422(20)30070-3
Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford). 2018;57(suppl_2):ii43-ii50. https://doi.org/10.1093/rheumatology/kex513
Cree BAC, Bennett JL, Kim HJ, et al.; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363. https://doi.org/10.1016/S0140-6736(19)31817-3
Collongues N, de Seze, J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord. 2016;9(3):180-188. https://doi.org/10.1177/1756285616632653
Collongues N, Brassat D, Maillart E, et al.; OFSEP and CFSEP. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler. 2016;22(7):955-959. https://doi.org/10.1177/1352458515602337
Poupart J, Giovannelli J, Deschamps R, et al.; NOMADMUS study group. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645-e1656. https://doi.org/10.1212/WNL.0000000000009245
Montcuquet A, Collongues N, Papeix C, et al.; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377-1384. https://doi.org/10.1177/1352458516678474
Zhang C, Tian DC, Yang CS, et al. Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2017;74(8):1010-1012. https://doi.org/10.1001/jamaneurol.2017.1336
Burt RK, Balabanov R, Han X, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732-e1741. https://doi.org/10.1212/WNL.0000000000008394
Crofford LJ, Nyhoff LE, Sheehan JH, et al. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. 2016, 12:763-773. https://doi.org/10.1586/1744666X.2016.1152888
Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972-988. https://doi.org/10.1080/21645515.2017.1316909
Peng J, Fu M, Mei H, et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol. 2022;32(3):e2295. https://doi.org/10.1002/rmv.2295